{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"description":"A TEAE was defined as any adverse events that occurred between the first dose of a study drug through 30 days after the last dose of any study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population: all participants who received ≥1 dose of avapritinib.","reportingStatus":"POSTED","timeFrame":"Baseline through Month 65","title":"Number of Participants Experiencing Treatment-emergent Adverse Events (TEAE)","type":"SECONDARY","unitOfMeasure":"Participants"}